Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. billion in 2029. More specifically, STX-241 targets exon 19 and exon 21 mutations alongside the co-occurring C797S mutation, whereas STX-721 focuses on exon 20 mutations. Up to 12.5% GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. COPD is the third leading cause of death worldwide, with 3.23 and drive the company’s market cap to almost $1.5

Pharma 57

Pharma Sales Leads Marketing 57

Pharmaceutical Technology

FEBRUARY 3, 2023

However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

Quantified

SEPTEMBER 21, 2023

through 2029. Use Cases for AI Tools for Sales The sales cycle is often divided into seven stages, from lead generation to completing a sale. AI Tools for Acquiring and Qualifying Leads Lead generation involves marketing campaigns, attending tradeshows, and making cold calls. The process is time and labor intensive.

Sales 52

Sales Prospecting Training Sales tools 52

European Pharmaceutical Review

OCTOBER 26, 2023

Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.

Patients 94

Patients Pharmaceutical Safety Marketing 94

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

European Pharmaceutical Review

NOVEMBER 16, 2023

billion by 2029. Prior to this role, Dr Terwey served as Vice President, Clinical Sciences, and the Global Development Lead for allogeneic CAR-T products at Atara Biotherapeutics. Additionally, the company ’s anti-PD-1 antibody achieved EU approval for oesophageal cancer in September 2023.

Medicine 52

Medicine Manufacturing Medical Patients 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143

Medical Prescription Management Manufacturing 143

Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

European Pharmaceutical Review

JANUARY 18, 2024

GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006).

Marketing 91

Marketing Sales Pharmacology Pharma 91

Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

European Pharmaceutical Review

AUGUST 30, 2022

million by 2029, up from $122.287 million in 2021. For example, standard nasal sprays feature swirl nozzles that typically have a spray cone angle of between 60 to 90 degrees, which can lead to most of the formulation hitting the walls of the nose, rather than penetrating further into the nasal cavity, impacting on dose uniformity.

Management 114

Management Manufacturing Marketing Side effects 114

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines. As the data landscape evolves, what is the most exciting innovation in clinical data management.

Safety 102

Safety Electronics Recruitment Medical 102

Pharmaceutical Technology

MARCH 7, 2023

billion by 2029, registering a CAGR of over 8% during the forecast period of 2022-2029. Maintaining dosing accuracy One company that is leading the way in powder products and dosing accuracy is Frewitt, an innovative manufacturer of premium-quality mills. Recent analysis valued the market [i] at USD 8.5

Distribution 52

Distribution Safety Management Manufacturing 52

Pharmaceutical Technology

MAY 17, 2023

This results in bile buildup in the liver and can lead to scarring. billion in 2029. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. The condition gradually worsens and can result in liver failure.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52